BioCryst appoints former FDA deputy center director Dr. Amy McKee to board of directors

BIOCRYST PHARMACEUTICALS INC

Board expanded from 10 to 11 members; Dr. McKee elected effective September 20, 2021.
Dr. McKee served as Deputy Center Director for FDA's Oncology Center of Excellence and is now VP at Parexel.
Dr. McKee to serve on Science Committee; receives initial grant of 53,333 stock options plus annual grants of 40,000 options.
Appointment brings regulatory expertise as BioCryst advances BCX9930 into pivotal trials for PNH and other complement diseases.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Amy McKee

Director

BCRX · BIOCRYST PHARMACEUTICALS INC

Effective: 2021-09-20
Filed: September 20, 2021, 7:59 PM ET

elected Amy McKee, M.D. to fill the vacancy created by the enlargement of the Board, effective September 20, 2021

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Amy McKee was elected as Director at BIOCRYST PHARMACEUTICALS INC.

Action: elected
Role: Director

Exact text from the filing

elected Amy McKee, M.D. to fill the vacancy created by the enlargement of the Board, effective September 20, 2021

View on SEC.gov

BIOCRYST PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001171843-21-006545

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.